Dosing Considerations for Tranexamic Acid in Patients with Renal Impairment

Introduction to Tranexamic Acid Use in Renal Impairment

The European Society of Cardiology recommends that tranexamic acid be used with caution in patients with renal impairment, as it is primarily eliminated by the kidneys, and its accumulation can occur in renal dysfunction 1
The American Heart Association suggests that the risk of toxic reactions, such as neurotoxicity and ocular toxicity, is higher in patients with altered renal function, emphasizing the need for dose reduction in renal impairment 1

The British Journal of Anaesthesia guidelines state that repeated doses of tranexamic acid should be used with caution in renal impairment due to its predominant renal excretion, and accumulation can occur in renal failure 2
The Critical Care journal recommends that in the context of trauma surgery, all antifibrinolytics, including tranexamic acid, are excreted renally and accumulate in renal failure, necessitating dose reduction 3
The European Heart Journal suggests that in patients with severe renal impairment (creatinine clearance <30 mL/min), the dose of tranexamic acid should be significantly reduced (50-70% reduction), and monitoring of plasma levels should be considered if available 4

The Journal of Hepatology recommends that in patients with cirrhosis, reduced doses of tranexamic acid are indicated in chronic or acute renal failure, and it should be used with caution 1
The European Heart Journal guidelines recommend that in elderly patients (>75 years), it should be assumed that renal function is decreased, and the dose of tranexamic acid should be adjusted prophylactically 4
The Anaesthesia journal states that tranexamic acid is contraindicated in subarachnoid hemorrhage due to the risk of cerebral edema and infarction 2

The European Heart Journal recommends maintaining adequate diuresis, especially important for dabigatran but applicable to all anticoagulants, and monitoring for signs of overdose, such as gastrointestinal symptoms, orthostatic hypotension, thromboembolic events, and neurological alterations 5
The European Heart Journal suggests that in severe renal impairment with prolonged use, consideration should be given to monitoring renal function to detect acute deterioration 4

For moderate renal impairment (creatinine clearance 30-60 mL/min), evidence supports downward dose adjustments, as renal clearance of tranexamic acid is reduced by 31-44% in this population, according to the National Comprehensive Cancer Network 6